Tolerogenixx, a biotechnology spinout of Heidelberg University Hospital, has raised an undisclosed amount of seed funding from public-private partnership High-Tech Gründerfonds (HTGF), according to FinSMEs.
Tolerogenixx develops bespoke cell therapy for immunosuppression in transplant patients without the usual negative side effects, such as increased risk of cancer.
The company will use the funds to prepare for the second phase of its clinical trial, commencing in spring 2018.
In the phase 1 clinical trial, the technique was applied to kidney transplants,…
